FDA expresses doubts about evidence on anemia drugs

09/10/2007 | Wall Street Journal (free content), The

The FDA discovered "important deficiencies" in data that support the beneficial effects of anemia treatment drugs Epogen and Aranesp made by Amgen and Procrit made by Johnson & Johnson. Studies that support quality-of-life improvement claims are limited and may not comply with current regulatory requirements, the FDA commented. More research is required to develop safer dosing recommendations, according to the FDA.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN